相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis
Susanne Gaul et al.
JOURNAL OF HEPATOLOGY (2021)
Gut microbial metabolites as multi-kingdom intermediates
Kimberly A. Krautkramer et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Gut microbiota in human metabolic health and disease
Yong Fan et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Phage Therapy for Alcohol-Associated Hepatitis
Gina A. Suh
HEPATOLOGY (2021)
Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy
Ivana Mikolasevic et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression
Marcello Dallio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low-grade inflammation via blockade of Kupffer cell M1 polarization
Yue Yin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD
Eduardo Vilar-Gomez et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2021)
Short-term overnutrition induces white adipose tissue insulin resistance through sn-1,2-diacylglycerol/PKC epsilon/insulin receptor Thr(1160) phosphorylation
Kun Lyu et al.
JCI INSIGHT (2021)
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches
Paola Dongiovanni et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates Nonalcoholic Steatohepatitis through Innate and Adaptive Signaling
Fanta Barrow et al.
HEPATOLOGY (2021)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Loomba et al.
HEPATOLOGY (2021)
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
V. Ratziu et al.
NATURE MEDICINE (2021)
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Roberto A. Calle et al.
NATURE MEDICINE (2021)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience
Roberto Scicali et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2021)
Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)
Lucia Lavin-Alconero et al.
TRIALS (2021)
Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice
Daniel Kucsera et al.
FRONTIERS IN PHYSIOLOGY (2021)
Extracellular Vesicles as Inflammatory Drivers in NAFLD
Akshatha N. Srinivas et al.
FRONTIERS IN IMMUNOLOGY (2021)
Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study
Emanuel Fryk et al.
EBIOMEDICINE (2021)
Role of Insulin Resistance in MAFLD
Yoshitaka Sakurai et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Histone Deacetylase 1 Reduces Lipogenesis by Suppressing SREBP1 Transcription in Human Sebocyte Cell Line SZ95
Hye Sun Shin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?
Johanna Heitmann et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)
Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis
Kunimaro Furuta et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
Alessandro Federico et al.
NUTRIENTS (2021)
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Oriol Juanola et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
Rosa Martin-Mateos et al.
FRONTIERS IN IMMUNOLOGY (2021)
Systematic review and network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Abdul M. Majzoub et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases
Chang Liu et al.
FASEB JOURNAL (2021)
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba et al.
GASTROENTEROLOGY (2021)
Unwrapping the mechanisms of ceramide and fatty acid-initiated signals leading to immune-inflammatory responses in obesity
Salih Kucuk et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
Nikolaos Perakakis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison et al.
NATURE MEDICINE (2021)
New targets for NAFLD
Lucia Parlati et al.
JHEP REPORTS (2021)
Non-alcoholic fatty liver disease: A patient guideline
Sven M. Francque et al.
JHEP REPORTS (2021)
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
Lee-Lee Lai et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients
Jessica R. Allegretti et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time
Pieter de Groot et al.
GUT (2020)
Association Between PNPLA3 rs738409 C > G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease
Stefania Grimaudo et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M. S. Capehorn et al.
DIABETES & METABOLISM (2020)
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
Fei Chen et al.
HEPATOLOGY (2020)
γδ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming
Alejandro Torres-Hernandez et al.
HEPATOLOGY (2020)
Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets
Seonghwan Hwang et al.
HEPATOLOGY (2020)
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure
Rudolf A. de Boer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Non-alcoholic fatty liver disease in inflammatory bowel disease patients
Katerina Karaivazoglou et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease
Eleonora Scorletti et al.
GASTROENTEROLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway
Charng-Cherng Chyau et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway
Hui-Min Wu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Hepatic NK cells attenuate fibrosis progression of non-alcoholic steatohepatitis in dependent of CXCL10-mediated recruitment
Yuting Fan et al.
LIVER INTERNATIONAL (2020)
Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial
Laura Craven et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Federica Zatterale et al.
FRONTIERS IN PHYSIOLOGY (2020)
Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways
Litao Wu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Characterization of the immune cell landscape of patients with NAFLD
Tom Diedrich et al.
PLOS ONE (2020)
Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels
Ahmed Abdallah Salman et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Lytic cell death in metabolic liver disease
Jeremie Gautheron et al.
JOURNAL OF HEPATOLOGY (2020)
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2020)
Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review
Katarzyna Kolczynska et al.
LIPIDS IN HEALTH AND DISEASE (2020)
A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression
Paula Iruzubieta et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Judith Aron-Wisnewsky et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways
Lamiaa A. Ahmed et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Guillaume Lassailly et al.
GASTROENTEROLOGY (2020)
Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease
Ekta Pandey et al.
FRONTIERS IN PHYSIOLOGY (2020)
Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity
Laura Antonucci et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis
Haiou Li et al.
FRONTIERS IN IMMUNOLOGY (2020)
Blocking integrin α4β7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis
Ravi P. Rai et al.
JOURNAL OF HEPATOLOGY (2020)
Comparison of MAFLD and NAFLD diagnostic criteria in real world
Su Lin et al.
LIVER INTERNATIONAL (2020)
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
Nikolaos Perakakis et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
A Membrane-Bound Diacylglycerol Species Induces PKC epsilon-Mediated Hepatic Insulin Resistance
Kun Lyu et al.
CELL METABOLISM (2020)
Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver
Anneleen Remmerie et al.
IMMUNITY (2020)
Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study
Rajaa Nahra et al.
JOURNAL OF HEPATOLOGY (2020)
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Sakura Yamamura et al.
LIVER INTERNATIONAL (2020)
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Patricia Rada et al.
CELL DEATH & DISEASE (2020)
Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD
Giljae Lee et al.
NATURE COMMUNICATIONS (2020)
Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
Carmelo Luci et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease
Tim Hendrikx et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Stratification of patients in NASH clinical trials: A pitfall for trial success
Javier Ampuero et al.
JHEP REPORTS (2020)
Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis
Kunimaro Furuta et al.
BIOLOGY-BASEL (2020)
Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis
Julia J. Witjes et al.
HEPATOLOGY COMMUNICATIONS (2020)
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis
Steven Young et al.
HEPATOLOGY COMMUNICATIONS (2020)
Animal models of NAFLD from a hepatologist's point of view
Daniel Jahn et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function
Suzanne R. Sharpton et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application
Dicky Struik et al.
CURRENT OPINION IN LIPIDOLOGY (2019)
Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease
Tawfik Khoury et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2019)
MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism
Seok-Ho Kim et al.
SCIENTIFIC REPORTS (2019)
Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
Ryo Goto et al.
FEBS OPEN BIO (2019)
The immunoregulatory effects of CD8 T-cell-derived perforin on diet-induced nonalcoholic steatohepatitis
Tianqi Wang et al.
FASEB JOURNAL (2019)
MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)
Veeral H. Ajmera et al.
HEPATOLOGY (2019)
Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Ashkan Afshin et al.
LANCET (2019)
Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes
Andreea-Manuela Mirea et al.
MOLECULAR MEDICINE (2019)
NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
Alex Depaoli et al.
DIABETES (2019)
Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis
Shinya Tsurusaki et al.
CELL DEATH & DISEASE (2019)
Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease
Natalie Stiglund et al.
FRONTIERS IN IMMUNOLOGY (2019)
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Valerio Rosato et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Ildiko Lingvay et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
The Obese Liver Environment Mediates Conversion of NK Cells to a Less Cytotoxic ILC1-Like Phenotype
Antonia O. Cuff et al.
FRONTIERS IN IMMUNOLOGY (2019)
MAIT cells in metabolic diseases
Leo Bertrand et al.
MOLECULAR METABOLISM (2019)
Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism
Jin Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Glucose-Sensing Transcription Factor MondoA/ChREBP as Targets for Type 2 Diabetes: Opportunities and Challenges
Ziyi Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Yi Duan et al.
NATURE (2019)
ILC-poiesis: Ensuring tissue ILC differentiation at the right place and time
Ai Ing Lim et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae (vol 30, pg 675, 2019)
Jing Yuan et al.
CELL METABOLISM (2019)
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Reenam S. Khan et al.
HEPATOLOGY (2019)
STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis
Yongsheng Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Metabolically healthy versus metabolically unhealthy obesity
Carla Iacobini et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues
Wan Mu et al.
FRONTIERS IN PHARMACOLOGY (2019)
Resolving the Paradox of Hepatic Insulin Resistance
Dominic Santoleri et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2019)
Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
James M. Paik et al.
HEPATOLOGY COMMUNICATIONS (2019)
Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies
Juha Mehtala et al.
DIABETOLOGY INTERNATIONAL (2019)
Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease
Suzanne R. Sharpton et al.
HEPATOLOGY COMMUNICATIONS (2019)
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli et al.
JHEP REPORTS (2019)
Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution
Joel T. Haas et al.
NATURE METABOLISM (2019)
Lifestyle modification in NAFLD/NASH: Facts and figures
Kate Hallsworth et al.
JHEP REPORTS (2019)
Metabolic Targets in Nonalcoholic Fatty Liver Disease
William P. Esler et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2019)
Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer
Rosa Divella et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice
Mitchell Bijnen et al.
GUT (2018)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
Yuya Seko et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Mice lacking PKC-theta in skeletal muscle have reduced intramyocellular lipid accumulation and increased insulin responsiveness in skeletal muscle
Bailey Peck et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2018)
Acetyl-CoA carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Eric J. Lawitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Alessandro Mantovani et al.
DIABETES CARE (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD)
Stefania Bruzzi et al.
FREE RADICAL BIOLOGY AND MEDICINE (2018)
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
Samar H. Ibrahim et al.
GUT (2018)
Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis
Dirk J. van der Windt et al.
HEPATOLOGY (2018)
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
Oliver Krenkel et al.
HEPATOLOGY (2018)
Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials
Cyrielle Caussy et al.
HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Fructose metabolism and metabolic disease
Sarah A. Hannou et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial
Nazarii Kobyliak et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2018)
Immune Responses in the Liver
Paul Kubes et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD
C. Caussy et al.
JOURNAL OF HEPATOLOGY (2018)
JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study
A. M. Diehl et al.
JOURNAL OF HEPATOLOGY (2018)
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra et al.
JOURNAL OF HEPATOLOGY (2018)
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial
Farnush Bakhshimoghaddam et al.
JOURNAL OF NUTRITION (2018)
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
Zobair M. Younossi
LIVER TRANSPLANTATION (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
The gut-liver axis and the intersection with the microbiome
Anupriya Tripathi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Mucosal-Associated Invariant T Cells in Chronic Inflammatory Liver Disease
Fabian J. Bolte et al.
SEMINARS IN LIVER DISEASE (2018)
Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver
Pushpa Hegde et al.
NATURE COMMUNICATIONS (2018)
Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
Kumiko Shiba et al.
SCIENTIFIC REPORTS (2018)
Dietary carbohydrates: role of quality and quantity in chronic disease
David S. Ludwig et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Dietary carbohydrates: role of quality and quantity in chronic disease
David S. Ludwig et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Innate Lymphoid Cells: 10 Years On
Eric Vivier et al.
CELL (2018)
Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release
Junjiang Pan et al.
CELLULAR IMMUNOLOGY (2018)
SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes
H. S. Bajaj et al.
DIABETES & METABOLISM (2018)
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEA (R) trial
Naveed Sattar et al.
DIABETOLOGIA (2018)
Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease
Jingjing Cai et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
Yuji Ogawa et al.
SCIENTIFIC REPORTS (2018)
Mucosal-Associated Invariant T Cells Improve Nonalcoholic Fatty Liver Disease Through Regulating Macrophage Polarization
Yanmei Li et al.
FRONTIERS IN IMMUNOLOGY (2018)
Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis
Igor Maricic et al.
JOURNAL OF IMMUNOLOGY (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
Francesco Bifari et al.
PHARMACOLOGICAL RESEARCH (2018)
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes
Rocio Aller de la Fuente et al.
ENDOCRINOLOGIA DIABETES Y NUTRICION (2018)
Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
Saba Sayari et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Natural History of Nonalcoholic Fatty Liver Disease: A Prospective Follow-Up Study With Serial Biopsies
Patrik Nasr et al.
HEPATOLOGY COMMUNICATIONS (2018)
Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Oliver Glass et al.
HEPATOLOGY COMMUNICATIONS (2018)
Posttranslational Modifications of Lipid-Activated Nuclear Receptors: Focus on Metabolism
Natalia Becares et al.
ENDOCRINOLOGY (2017)
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial
Catherine M. Viscoli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Akio Ohta et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis
Cristina Alonso et al.
GASTROENTEROLOGY (2017)
Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease
Hironori Mitsuyoshi et al.
HEPATOLOGY RESEARCH (2017)
Adapting to obesity with adipose tissue inflammation
Shannon M. Reilly et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner
Fenglei Li et al.
NATURE COMMUNICATIONS (2017)
Meta-analysis of gut microbiome studies identifies disease-specific and shared responses
Claire Duvallet et al.
NATURE COMMUNICATIONS (2017)
Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4-MD2 complex
So Yeon Kim et al.
NATURE COMMUNICATIONS (2017)
The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial
Leila Javadi et al.
IRANIAN RED CRESCENT MEDICAL JOURNAL (2017)
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis A Meta-analysis
Giovanni Musso et al.
JAMA INTERNAL MEDICINE (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study
Yaru Li et al.
PLOS ONE (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition
Ruud S. Kootte et al.
CELL METABOLISM (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus
Yukihiro Bando et al.
DIABETOLOGY INTERNATIONAL (2017)
TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival
Auvro R. Mridha et al.
CLINICAL SCIENCE (2017)
Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice
Rongying Ou et al.
ENDOCRINE (2017)
The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice
Beihui He et al.
BMC IMMUNOLOGY (2017)
Hepatic Natural Killer T-Cell and CD8+ T-Cell Signatures in Mice with Nonalcoholic Steatohepatitis
Jashdeep Bhattacharjee et al.
HEPATOLOGY COMMUNICATIONS (2017)
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
CELL METABOLISM (2017)
Treating Fatty Liver Disease by Modulating Mitochondrial Pyruvate Metabolism
Jerry R. Colca et al.
HEPATOLOGY COMMUNICATIONS (2017)
Liver macrophages in tissue homeostasis and disease
Oliver Krenkel et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients
Reem Z. Sharaiha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome
Magar Ghazarian et al.
SCIENCE IMMUNOLOGY (2017)
Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study
Amalia Gastaldelli et al.
DIABETES (2017)
Hepatocytes: a key cell type for innate immunity
Zhou Zhou et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice
Simona Rolla et al.
CLINICAL SCIENCE (2016)
Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis
Stergios A. Polyzos et al.
DIABETOLOGIA (2016)
Association of body composition and eating behavior in the normal weight obese syndrome
Laura Di Renzol et al.
EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY (2016)
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
Raymond Kwok et al.
GUT (2016)
Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver
Monika Rau et al.
JOURNAL OF IMMUNOLOGY (2016)
Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner
Eiji Kakazu et al.
JOURNAL OF LIPID RESEARCH (2016)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Joel T. Haas et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
Takamasa Ohki et al.
CLINICAL DRUG INVESTIGATION (2016)
Innate Immunity and Inflammation in NAFLD/NASH
Marco Arrese et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota
Jerome Boursier et al.
HEPATOLOGY (2016)
NKp46+ Natural Killer Cells Attenuate Metabolism-Induced Hepatic Fibrosis by Regulating Macrophage Activation in Mice
Annie-Carole Tosello-Trampont et al.
HEPATOLOGY (2016)
ChREBP regulates fructose-induced glucose production independently of insulin signaling
Mi-Sung Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9
Irma Garcia-Martinez et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells
Feng Zhang et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2
Dewei Ye et al.
JOURNAL OF HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial
Golnaz Ekhlasi et al.
JOURNAL OF RESEARCH IN MEDICAL SCIENCES (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Manoela Mota et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma et al.
NATURE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Durable coexistence of donor and recipient strains after fecal microbiota transplantation
Simone S. Li et al.
SCIENCE (2016)
The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis
Mark A. Herman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity
Naoto Kubota et al.
NATURE COMMUNICATIONS (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4
Yuxin Shu et al.
ONCOTARGET (2016)
ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch
Steven Zhao et al.
CELL REPORTS (2016)
Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials0
Nadja B. Kristensen et al.
GENOME MEDICINE (2016)
The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
Gabriele Forlani et al.
JOURNAL OF DIABETES RESEARCH (2016)
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda et al.
PLOS ONE (2016)
Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation
D. T. Reid et al.
PLOS ONE (2016)
The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial
Atefe Asgharian et al.
INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE (2016)
Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis
Benjamin Pulli et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease
N. U. Ashraf et al.
FREE RADICAL RESEARCH (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease
Johannie du Plessis et al.
GASTROENTEROLOGY (2015)
Dysbiosis-Induced Intestinal Inflammation Activates Tumor Necrosis Factor Receptor I and Mediates Alcoholic Liver Disease in Mice
Peng Chen et al.
HEPATOLOGY (2015)
Effect of Vildagliptin on Hepatic Steatosis
Mavin Macauley et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
NAFLD: A multisystem disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Su Jong Yu et al.
MEDICINE (2015)
The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease
Maria Teresa Arias-Loste et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic
Chris J. Weston et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Association between Complement C3 and Prevalence of Fatty Liver Disease in an Adult Population: A Cross-Sectional Study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) Cohort Study
Qiyu Jia et al.
PLOS ONE (2015)
Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
Tannaz Eslamparast et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2014)
M2 Kupffer Cells Promote M1 Kupffer Cell Apoptosis: A Protective Mechanism Against Alcoholic and Nonalcoholic Fatty Liver Disease
Jinghong Wan et al.
HEPATOLOGY (2014)
IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
Isaac T. W. Harley et al.
HEPATOLOGY (2014)
The Portal Inflammatory Infiltrate and Ductular Reaction in Human Nonalcoholic Fatty Liver Disease
Victoria L. Gadd et al.
HEPATOLOGY (2014)
3, 3′-diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance
Yun Liu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Glucose Transporter 8 (GLUT8) Mediates Fructose- induced de Novo Lipogenesis and Macrosteatosis
Brian J. DeBosch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis
Xiang Zhang et al.
JOURNAL OF HEPATOLOGY (2014)
Synthesis of IL-6 by Hepatocytes Is a Normal Response to Common Hepatic Stimuli
Callie A. Norris et al.
PLOS ONE (2014)
A Small Amount of Dietary Carbohydrate Can Promote the HFD-Induced Insulin Resistance to a Maximal Level
Shuang Mei et al.
PLOS ONE (2014)
Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease
Davide Povero et al.
PLOS ONE (2014)
IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet
Xiao-Yu Luo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASH
Lixin Zhu et al.
HEPATOLOGY (2013)
Toll-Like Receptor 2 and Palmitic Acid Cooperatively Contribute to the Development of Nonalcoholic Steatohepatitis Through Inflammasome Activation in Mice
Kouichi Miura et al.
HEPATOLOGY (2013)
PPARγ signaling and metabolism: the good, the bad and the future
Maryam Ahmadian et al.
NATURE MEDICINE (2013)
Inflammation and Lipid Signaling in the Etiology of Insulin Resistance
Christopher K. Glass et al.
CELL METABOLISM (2012)
Circulating Microparticles as Disease-Specific Biomarkers of Severity of Inflammation in Patients With Hepatitis C or Nonalcoholic Steatohepatitis
Miroslaw Kornek et al.
GASTROENTEROLOGY (2012)
Sterile Inflammation in the Liver
Paul Kubes et al.
GASTROENTEROLOGY (2012)
Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice
Fanli Meng et al.
GASTROENTEROLOGY (2012)
Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome
Anne Vrieze et al.
GASTROENTEROLOGY (2012)
Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase
Laura Gomez-Santos et al.
HEPATOLOGY (2012)
The Role of Innate Cells Is Coupled to a Th1-Polarized Immune Response in Pediatric Nonalcoholic Steatohepatitis
Nazarena E. Ferreyra Solari et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver
Renaud Dentin et al.
JOURNAL OF HEPATOLOGY (2012)
Neutrophil-Derived Myeloperoxidase Aggravates Non-Alcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Deficient Mice
Sander S. Rensen et al.
PLOS ONE (2012)
Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis
Cecilia Soderberg et al.
APMIS (2011)
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Y. Tang et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Altered Phenotype and Functionality of Circulating Immune Cells Characterize Adult Patients with Nonalcoholic Steatohepatitis
Maria Eugenia Inzaugarat et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Increased production of sonic hedgehog by ballooned hepatocytes
Fatima Rangwala et al.
JOURNAL OF PATHOLOGY (2011)
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Intrahepatic natural killer T cell populations are increased in human hepatic steatosis
Michael Adler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Kupffer Cell and Interleukin-12-Dependent Loss of Natural Killer T Cells in Hepatosteatosis
Michael Kremer et al.
HEPATOLOGY (2010)
Major Histocompatibility Complex Class I-Related Chains A and B (MIC A/B): A Novel Role in Nonalcoholic Steatohepatitis
Alisan Kahraman et al.
HEPATOLOGY (2010)
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Accumulation of Natural Killer T Cells in Progressive Nonalcoholic Fatty Liver Disease
Wing-Kin Syn et al.
HEPATOLOGY (2010)
Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet
Takuya Miyagi et al.
JOURNAL OF GASTROENTEROLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Roles of liver innate immune cells in nonalcoholic fatty liver disease
Yu-Tao Zhan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis
Sander S. Rensen et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Role of liver-infiltrating CD3(+)CD56(+) natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease
Kazuto Tajiri et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Activation of the Complement System in Human Nonalcoholic Fatty Liver Disease
Sander S. Rensen et al.
HEPATOLOGY (2009)
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity
Satoshi Nishimura et al.
NATURE MEDICINE (2009)
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease
ZP Li et al.
HEPATOLOGY (2005)
Apoptosis in alcoholic and nonalcoholic steatohepatitis
AE Feldstein et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression
A Canbay et al.
HEPATOLOGY (2003)
分享论文
